Abstract 272P
Background
Prostate cancer was the second most commonly diagnosed cancer in men and is responsible for the fifth highest number of deaths globally. In its early stages, prostate cancer may not exhibit any noticeable symptoms and often progresses slowly, so that it requires active surveillance and detection. Standard biopsy of the prostate that is typically performed using TRUS guidance is one of commonly detection used for prostate cancer. However, several studies showed that MRI-targeted biopsy has better accuracy than standard biopsy. Thus, this meta-analysis aims to evaluate which examination has the ability to detect prostate cancer better between MRI-targeted or standard biopsy.
Methods
Studies were extracted from PubMed databases using several keywords such as ((mri targeted) AND (standard biopsy)) AND (prostate cancer) on May 25th, 2023. Extracted studies were selected through several inclusion criteria, such as randomized controlled trials and cohorts in the last 10 years and exclusion criteria, such as meta-analysis, reviews, case reports and unavailability of full paper access. The quality of the included studies were assessed using Newcastle-Ottawa Scale (NOS) and JADAD scale.
Results
Six total studies were included in these studies, consist of three cohort studies and three RCTs with 4867 mens under suspicion for prostate cancer. Five out of six studies were in good quality, while the other one have fair quality. Meta-analysis showed that MRI-targeted biopsy had a higher detection rate than standard biopsy for prostate cancer with Odds Ratio (M-H, Random Effect Model, 95% CI) 1.72 [0.97, 3.06]. This result proved that MRI-targeted biopsy is superior to standard biopsy for detecting prostate cancer.
Conclusions
In conclusion, detection for prostate cancer is better with MRI-targeted biopsy than standard biopsy due to higher detection rate in MRI-targeted biopsy. However, further studies were required to confirm these findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract